Search Results - "Purohit, Parva"

Development of orally bioavailable prodrugs of fulvestrant for the treatment of metastatic/advanced breast cancer by Purohit, Parva, Brahmkshatriya, Pathik, Goswami, Vishalgiri

“…Abstract only e13027 Background: Fulvestrant, a potent, selective estrogen receptor degrader, is a primary drug of choice for treating advanced metastatic…”
Get full text

MP03-01 THE EVOLVING STORY OF PHENAZOPYRIDINE: EXPLORING THE PHARMACOLOGICAL EFFECTS IN ANIMAL MODELS OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME by Purohit, Parva, Pandya, Heta, Jash, Kavya, Unadkat, Vishal, Variya, Ketan, Sangle, Ganesh

Get full text

Identification, synthesis, and characterization of an unprecedented N‐(2‐carboxyethyl) adduct impurity in an injectable ganirelix formulation by Jadav, Rohit, Kameriya, Ramraj, Chatterjee, Saurav, Gour, Vinod, Purohit, Parva, Bandyopadhyay, Anupam

“…Ganirelix, a peptide‐based drug used to treat female infertility, has been in high market demand, which attracted generic formulation. A hitherto unknown…”
Get full text

Abstract 1616: Preclinical characterization of KSHN001126, a novel, differentiated and steroidal oral selective estrogen receptor degrader (SERD) by Purohit, Parva, Pandya, Heta, Unadkat, Vishal, Variya, Ketan, Sinha, Sonam, Barmade, Mahesh, Rohit, Shishir, Sangle, Ganesh

“…Abstract Fulvestrant (FLV) (Faslodex®) is the only clinically approved steroidal SERD that requires painful intramuscular administration. Several oral SERDs…”
Get full text

Abstract 4043: KSHN001034: An intramuscular prodrug of fulvestrant to treat estrogen-receptor (ER) positive advanced metastatic breast cancer by Pandya, Heta, Sangle, Ganesh, Unadkat, Vishal, Goswami, Vishal, Purohit, Parva, Mehta, Chirag, Sinha, Sonam, Variya, Ketan

“…Abstract Purpose: Breast cancer (BC) remains a considerable health concern, with over 75% of total cases accounting for ER+ BC. Fulvestrant, a selective…”
Get full text

Abstract 3356: Comparative analysis of approved and undertrial SERDs in estrogen receptor-α (ERα): An in-silico approach by Unadkat, Vishal, Rohit, Shishir, Purohit, Parva, Mehta, Chirag, Goswami, Vishal, Barmade, Mahesh, Sinha, Sonam, Sangle, Ganesh

“…Abstract Background: Despite recent advancements in early detection and treatment, breast cancer is the second most common cancer affecting women globally,…”
Get full text

Abstract 3077: Pharmacological profiling of KSHN001034 - A novel prodrug of Fulvestrant with improved efficacy by Purohit, Parva, Pandya, Heta, Unadkat, Vishal, Mehta, Sandip, Variya, Ketan, Sinha, Sonam, Barmade, Mahesh, Krishna, Vamsi, Sangle, Ganesh

“…Abstract Purpose: KSHN001034, a Fulvestrant (FLV) prodrug, was developed to enhance solubility and achieve higher FLV plasma exposures. Currently, Faslodex®…”
Get full text